New attention disorder could equal a big new ADHD drug market. But is it legit?
14.04.2014 / Fierce Pharma
There could be a new attention disorder on the block in the future–one that could open up a new patient pool for ADHD drugmakers Eli Lilly, Shire and others. But with pharma critics adept at pointing fingers at companies for "disease-mongering," it's one that could open up a new round of controversy, too.